Yesterday Bristol-Myers Squibb
The data involved the drug's use in adolescents. Patients in the moderately sized 300-person study who were treated with Abilify experienced a large statistically significant reduction in schizophrenia symptoms compared to placebo and suffered no usual side effects.
Since there are no formally approved atypical anti-psychotics to treat schizophrenia in adolescents, if Bristol-Myers can expand Abilify's label to treat this patient group then it will have a good marketing edge versus the other atypical anti-psychotics.
The $16 billion anti-psychotic drug market, composed of compounds like Abilify and Eli Lilly's
Abilify does have some patent issues hanging over it that may affect its future sales. (Bristol-Myers shares part of the revenue it generates from Abilify with partner Otsuka Pharmaceuticals.) But with sales growth of nearly 30% in the first quarter and Abilify accounting for over 10% of its pharmaceutical segment revenues, it is one of Bristol-Myers' most important and fastest-growing compounds. The more data that Bristol-Myers puts out about Abilify that is positive, the more on- and off-label prescriptions of the drug will grow.
Looking for more Foolish drug stock coverage? Check out the Fool's market-beating Rule Breakers newsletter. You can check out all our recommendations as well as get access to our message boards and exclusive content with a 30-day free trial.